Results 51 to 60 of about 171,936 (295)
Trial watch: DNA-based vaccines for oncological indications
OncoImmunology, 2017 DNA-based vaccination is a promising approach to cancer immunotherapy. DNA-based vaccines specific for tumor-associated antigens (TAAs) are indeed relatively simple to produce, cost-efficient and well tolerated.
Stefano Pierini +7 more
doaj +1 more source
, 2021 Chikungunya virus (CHIKV) infection can result in chronic and debilitating arthralgia affecting humans in tropical and subtropical regions around the world, yet there are no licensed vaccines to prevent infection.
Brian Fouty +11 more
core +1 more source
Mesoporous Silica Nanoparticles in Biomedicine: Advances and Prospects
Advanced Materials, EarlyView.Mesoporous silica nanoparticles offer unique properties like high surface area, tunable pores, and functionalization. They excel in drug delivery, tissue engineering, and stimuli‐responsive therapies, enabling targeted and controlled treatments. With roles in cancer therapy and diagnostics, their clinical translation requires addressing challenges in ...
Miguel Manzano, María Vallet‐Regí
wiley +1 more source
DNA vaccines for biodefense [PDF]
Expert Review of Vaccines, 2009 An ideal biodefense vaccine platform would allow for the quick formulation of novel vaccines in response to emerging or engineered pathogens. The resultant vaccine should elicit protective immune responses in one to three doses and be unaffected by pre-existing immunity to vaccine components.
Dupuy, Lesley C., Schmaljohn, Connie S.
openaire +2 more sources
, 2008 The majority of known human tumor-associated antigens derive from non-mutated self proteins. T cell tolerance, essential to prevent autoimmunity, must therefore be cautiously circumvented to generate cytotoxic T cell responses against these targets.
Buchan, Sarah L. +21 more
core +1 more source
Advanced Materials, EarlyView.Inspired by viral entry mechanisms, the FUSION assay enables autonomous detection of respiratory viruses via membrane fusion–triggered CRISPR‐Cas13a activation. VEACON selectively fuses with fusion‐competent viruses, triggering fluorescence within confined vesicles.
Jae Chul Park +15 more
wiley +1 more source
New insights for the development of efficient DNA vaccines
Microbial BiotechnologyDespite the great potential of DNA vaccines for a broad range of applications, ranging from prevention of infections, over treatment of autoimmune and allergic diseases to cancer immunotherapies, the implementation of such therapies for clinical ...
Simone Berger +3 more
doaj +1 more source
Advanced Science, EarlyView.sEVs‐circ6718 serves as a promising serum biomarker for gastric cancer early diagnosis and prognosis, promoting malignant transformation in gastric cancer cells and GC‑MSC differentiation into CAFs. sEVs‑circ6718 holds potential as a biomarker for the early diagnosis and prognostic assessment of gastric cancer.
Fan Zhang +7 more
wiley +1 more source
Advanced Science, EarlyView.Prostate cancer is immunologically ‘cold’, with scarce, dysfunctional type 1 conventional dendritic cells (cDC1s) that limit T cell priming. We introduce an aptamer‐targeted liposomedelivering FMS‐like tyrosine kinase 3 ligand (Flt3L) and chlorin e6 (Ce6). Ultrasound induces antigen release and cDC1s recruitment, creating an in situ cDC1 vaccine.
Jiayi Wang +8 more
wiley +1 more source
In vitro transcribed RNA-based platform vaccines : past, present, and future
, 2023 mRNA was discovered in 1961, but it was not used as a vaccine until after three decades. Recently, the development of mRNA vaccine technology gained great impetus from the pursuit of vaccines against COVID-19.
Perenkov, Alexey D. +7 more
core +1 more source